[DOI] [PubMed] [Google Scholar] 90.Strinic D., Belosic Halle Z., Luetic K., Nedic A., Petrovic I., Sucic M., Zivanovic Posilovic G., Balenovic D., Strbe S., Udovicic M., et al
One clinical trial from 2025 on participants with obesity (but without diabetes) concluded that tirzepatide was superior with respect to reduction in body weight and waist circumference. Research in this area is ongoing, but tirzepatides prospects are certainly promising so far
There is overwhelming evidence that demonstrates that elevated calcium concentration, inflammation, increased oxidative stress, as well as a reduction in blood flow, are some of the pathophysiological mechanisms underlying NIHL (Figure 1
In a statement, Mochi said it doesn't anticipate any interruptions or delays in patient care as a result of this lawsuit, and that it remains confident in the integrity of its clinical approach
Wu, Q., Howell, M
References This article draws on peer-reviewed pharmacokinetic and clinical research on oral glutathione bioavailability and safety, established nephrology literature on renal glutathione physiology and oxidative stress, published data on N-Acetyl Cysteine (NAC) in contrast-induced nephropathy prevention, and India's CDSCO public advisory on injectable glutathione (issued May 18, 2026)
